Taro-Atenolol 100 mg – DIN 02267993
Taro-Atenolol is Atenolol 100 mg (tablet), sold in Canada. It is used for high blood pressure, heart failure and chest pain (angina). It is supplied by Sun Pharma Canada Inc. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.
Sold in Canada
Atenolol 100 mg
- Brand
- Taro-Atenolol
- Strength
- 100 mg
- Used for
- High blood pressure, heart failure and chest pain (angina)
- Form
- Tablet
- Manufacturer
- Sun Pharma Canada Inc
- Drug class
- Beta blocker (heart and blood pressure medicine)
- Sold in
- Canada
- DIN
- 02267993
Source: Health Canada's Drug Product Database. Last checked .
Report a mistake
What is Atenolol used for?
Atenolol is used for high blood pressure, heart failure, chest pain (angina) and atrial fibrillation (irregular heartbeat).
- Medicine type
- Beta blocker (heart and blood pressure medicine)
Official uses from the US prescribing label
Hypertension
Atenolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
Atenolol tablets may be administered with other antihypertensive agents.
Angina Pectoris Due to Coronary Atherosclerosis
Atenolol tablets are indicated for the long-term management of patients with angina pectoris.
Acute Myocardial Infarction
Atenolol tablets are indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment can be initiated as soon as the patient's clinical condition allows. (See DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and WARNINGS.) In general, there is no basis for treating patients like those who were excluded from the ISIS-1 trial (blood pressure less than 100 mm Hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta-blockade. As noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm Hg) seemed less likely to benefit.
From the FDA-approved label on DailyMed (published Sep 29, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your medicine? Check the box
- The box or bottle shows DIN 02267993.
- It names Taro-Atenolol, Atenolol 100 mg.
- A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.
Sold in Canada as Taro-Atenolol by Sun Pharma Canada Inc.
In Canada: prescription only.
Ingredients
Active: Atenolol
Other Atenolol pills
-
Z 65
Atenolol 25 mg
White, round, 6 mm
Used for high blood pressure and heart failure
- DAN 50 5777 Atenolol White, round, 9 mm Used for high blood pressure and heart failure
- 5778 Dan 100 Atenolol White, round, 7 mm Used for high blood pressure and heart failure
- 264 Atenolol White, round, 6 mm Used for high blood pressure and heart failure
- 265 Atenolol White, round, 7 mm Used for high blood pressure and heart failure
- 266 Atenolol White, round, 9 mm Used for high blood pressure and heart failure
- DAN 100 5778 Atenolol 100 mg White, round, 7 mm Used for high blood pressure and heart failure
- RE 21 Atenolol 100 mg White, round, 9 mm Used for high blood pressure and heart failure